SCHEMBL3042901

SCHEMBL3042901

Nc1nc2c(ncn2[C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)c(=O)[nH]1

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.81
P2RY2 P41231 2/20 0.74
P2RY4 P51582 2/20 0.74
P2RY6 Q15077 2/20 0.74
TGM2 P21980 1/20 0.60
FUT5 Q11128 1/20 0.60
KRAS P01116 2/20 0.59
POLG P54098 1/20 0.57
NT5E P21589 2/20 0.56
PNP P00491 1/20 0.55
DTYMK P23919 4/20 0.55
P2RX3 P56373 1/20 0.51
ENPP1 P22413 1/20 0.51
P2RY1 P47900 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16699229 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL28008515 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL13111568 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL2820367 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL252797 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL80609 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL18785123 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL12729493 1.00 POLB (0.81) POLBP2RY2P2RY4P2RY6TGM2
Deoxyguanosine Triphosphate SCHEMBL4558366 0.99 POLB (0.80) POLBP2RY2P2RY4P2RY6TGM2
SCHEMBL18785152 0.99 POLB (0.82) POLBP2RY2P2RY4P2RY6TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250369027-A1 SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS TWIST BIOSCIENCE CORP (US) 2025-12-04 US claimed
CN-119677866-A Substrate cleavage for nucleic acid synthesis 特韦斯特生物科学公司 2025-03-21 CN claimed
EP-4504959-A1 SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS Twist Bioscience Corporation (US) 2025-02-12 EP claimed
US-20240344057-A1 METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES Twist Bioscience Corporation 2024-10-17 US claimed
WO-2023196499-A1 SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS Twist Bioscience Corporation (US) 2023-10-12 WO claimed
EP-4229210-A1 METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES Twist Bioscience Corporation (US) 2023-08-23 EP claimed
WO-2022086866-A1 METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES Twist Bioscience Corporation (US) 2022-04-28 WO claimed
US-20260132223-A1 CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES ANSA BIOTECHNOLOGIES INC (US) 2026-05-14 US disclosed
EP-4731762-A2 DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES Ansa Biotechnologies, Inc. (US) 2026-04-29 EP disclosed
US-20250369027-A1 SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS TWIST BIOSCIENCE CORP (US) 2025-12-04 US disclosed
EP-4594480-A2 CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES Ansa Biotechnologies, Inc. (US) 2025-08-06 EP disclosed
WO-2024073349-A9 CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES ANSA BIOTECHNOLOGIES, INC. (US) 2025-04-03 WO disclosed
CN-119677866-A Substrate cleavage for nucleic acid synthesis 特韦斯特生物科学公司 2025-03-21 CN disclosed
US-20150090936-A1 LARGE STOKES SHIFT DYES Life Technologies Corporation 2015-04-02 US disclosed
EP-2836604-A2 METHOD OF PREPARATION OF NANOPORE AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2015-02-18 EP disclosed
WO-2013191793-A1 NUCLEIC ACID SEQUENCING BY NANOPORE DETECTION OF TAG MOLECULES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-12-27 WO disclosed
WO-2013154999-A2 METHOD OF PREPARATION OF NANOPORE AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-10-17 WO disclosed
US-20110313129-A1 LARGE STOKES SHIFT DYES Life Technologies Corporation (US) 2011-12-22 US disclosed
EP-2396318-A2 LARGE STOKES SHIFT DYES Life Technologies Corporation (US) 2011-12-21 EP disclosed
WO-2010093726-A2 LARGE STOKES SHIFT DYES Life Technologies Corporation (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150090936-A1 LARGE STOKES SHIFT DYES SLC7A5, SLC43A1, HCCS POLB 4822/4885P2RY2 4248/4885P2RY4 3214/4885
US-20110313129-A1 LARGE STOKES SHIFT DYES SLC7A5, SLC43A1, HCCS POLB 4822/4885P2RY2 4248/4885P2RY4 3214/4885
US-20260132223-A1 CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES POLN, PCNA, POLB POLB 3/4885P2RY2 3845/4885P2RY4 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.